Abstract: A smart wheel chock includes a chock body including a ground engaging surface and a wheel engaging surface for engaging a wheel of a vehicle; a processor housed within the chock body; a position tracking sensor housed within the chock body, wherein the position tracking sensor is configured to detect a location of the wheel chock; a wireless communication module in communication with the processor and configured to transmit the location of the wheel chock; a power system configured to supply power to the processor and wireless communication module; and a visual indicator on the chock body, wherein the visual indicator is configured to be visible while the chock body is engaged with the wheel, and wherein the visual indicator includes a unique identifier for the smart wheel chock.

Abstract: The present invention relates to an improved process for the preparation of Melphalan, more specifically the invention relates to an efficient process for the preparation of substantially pure Melphalan hydrochloride (I).

Abstract: The present invention discloses a means to improve stability, dissolution, and in vivo bioavailability of non-aqueous oral formulations containing natural or synthetic cannabinoid derivatives. In particular, this invention provides a non-aqueous cannabinoid formulation containing zero amount of water with one or more organic solvents, surfactants, co-surfactants, semi-polar solvents and mono-di glycerides. Upon administration, these formulations produce nano-sized cannabinoid liquid globules.

Abstract: The present invention relates to an improved process for the preparation of Melphalan, more specifically the invention relates to an efficient process for the preparation of substantially pure Melphalan hydrochloride (I).

Abstract: A process for the extraction and purification of recombinant proteins, more specifically interferons and insulin, having improved quality and yield. The process comprises extraction of proteins from bacterial inclusion bodies using an extraction solution comprising at least one detergent; at least one chaotropic agent; at least one cosmotropic agent; and a protein folding agent.

Abstract: This invention relates to pharmaceutical dosage forms for delivery of drugs susceptible to abuse, such as, for example, oxycodone and/or oxymorphone.

Abstract: The invention describes a blister packaging system, and method of making the system, capable of establishing and maintaining arid and anaerobic conditions for packaging pharmaceutical products that are sensitive to oxygen and/or moisture. The blister packaging system encompasses, for example, a scaffold of several interconnected cavities intended for product and one or more reservoirs comprising an oxygen scavenger and/or a desiccant. Furthermore, the concentration of the components is maintained at a level that prevents establishment of equilibrium conditions.

Abstract: Cephem compounds, pharmaceutically acceptable salts thereof, and methods of using same, wherein the compound has a bicyclic nitrogen-containing aromatic heterocyclic ring as the quaternary ammoniomethyl group at the 3-position and one or both of a terminal amidine residue (substituted or unsubstituted) attached to an aryl or a 5- or 6-membered heteroaryl group (substituted or unsubstituted) which is further attached through a spacer to the free N-atom of the quaternary nitrogen-containing bicyclic ring at the 3-side chain, or a terminal guanidine residue attached to an aryl or a 5- or 6-membered heteroaryl group (substituted or unsubstituted) which is further attached through a spacer to the free N-atom of the quaternary nitrogen-containing bicyclic ring at the 3-side chain.

Abstract: Cephem compounds, pharmaceutically acceptable salts thereof, and methods of using same, wherein the compound has a bicyclic nitrogen-containing aromatic heterocyclic ring as the quaternary ammoniomethyl group at the 3-position and one or both of a terminal amidine residue (substituted or unsubstituted) attached to an aryl or a 5- or 6-membered heteroaryl group (substituted or unsubstituted) which is further attached through a spacer to the free N-atom of the quaternary nitrogen-containing bicyclic ring at the 3-side chain, or a terminal guanidine residue attached to an aryl or a 5- or 6-membered heteroaryl group (substituted or unsubstituted) which is further attached through a spacer to the free N-atom of the quaternary nitrogen-containing bicyclic ring at the 3-side chain.

Abstract: The present invention relates to an improved process for the preparation of Melphalan, more specifically the invention relates to an efficient process for the preparation of substantially pure Melphalan hydrochloride (I).

Abstract: The present invention relates to a process for the preparation of substantially pure 2-cyanoimino-1,3-thiazolidine of Formula (I) by cyclization of dimethyl N-cyanoiminodithiocarbonate with 2-aminoethanethiol or the salt thereof in the presence of an alkali metal alkoxide. Further the present invention provides a process for the preparation of substantially pure 2-cyanoimino-1,3-thiazolidine of Formula (I) by cyclization of dimethyl N-cyanoiminodithiocarbonate with 2-aminoethanethiol or the salt thereof in the presence of aqueous ammonia.

Abstract: A novel pharmaceutical composition including thieno-pyridine derivatives, primarily ticlopidine hydrochloride, having no other organic or inorganic acid stabilizing agents or metal stearates. The stable pharmaceutical composition also includes hydrogenated vegetable oil as lubricant and other suitable non-ionic inert pharmaceutical excipients.

Abstract: Cephem compounds, pharmaceutically acceptable salts thereof, and methods of using same, wherein the compound has a bicyclic nitrogen-containing aromatic heterocyclic ring as the quaternary ammoniomethyl group at the 3-position and one or both of a terminal amidine residue (substituted or unsubstituted) attached to an aryl or a 5- or 6-membered heteroaryl group (substituted or unsubstituted) which is further attached through a spacer to the free N-atom of the quaternary nitrogen-containing bicyclic ring at the 3-side chain, or a terminal guanidine residue attached to an aryl or a 5- or 6-membered heteroaryl group (substituted or unsubstituted) which is further attached through a spacer to the free N-atom of the quaternary nitrogen-containing bicyclic ring at the 3-side chain.